SCHEMBL6033347

SCHEMBL6033347

CC1(C)CCC(C)(C)c2cc([Se]c3ccc(C(=O)O)cn3)ccc21

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXRA P19793 15/20 0.56
RXRB P28702 13/20 0.56
RXRG P48443 11/20 0.56
RARB P10826 8/20 0.56
RARG P13631 7/20 0.56
RARA P10276 6/20 0.53
CYP26A1 O43174 4/20 0.52
CYP3A4 P08684 3/20 0.52
CYP26B1 Q9NR63 2/20 0.52
CRABP2 P29373 1/20 0.52
PPARG P37231 1/20 0.51
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
CYP2C19 P33261 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6033065 0.83 RXRA (0.66) RXRARXRBRXRGRARBRARG
SCHEMBL4956919 0.81 RXRA (0.51) RXRARXRBRXRGRARBRARG
SCHEMBL6033044 0.81 RXRA (0.59) RXRARXRBRXRGRARBRARG
SCHEMBL6878104 0.78 RXRA (0.51) RXRARXRBRXRGRARBRARG
SCHEMBL7670810 0.78 RXRA (0.51) RXRARXRBRXRGRARBRARG
SCHEMBL29827631 0.78 RARB (0.81) RXRARXRBRXRGRARBRARG
SCHEMBL846110 0.78 RARB (0.81) RXRARXRBRXRGRARBRARG
SCHEMBL6033014 0.78 RARG (0.45) RXRARXRBRXRGRARBRARG
SCHEMBL6033247 0.77 GCK (0.42) RXRARXRBRXRGRARBRARG
SCHEMBL6033132 0.76 RARB (0.56) RXRARXRBRXRGRARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6992094-B1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-31 US claimed
EP-1086080-B1 DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2004-08-25 EP claimed
US-6992094-B1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-31 US disclosed
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics TYR, DERL1, GPX1 RXRA 1865/4885RXRB 1881/4885RXRG 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.